Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3-1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects

Investigational New Drugs

Volumn 34, Issue 2, 2016, Pages 202-215

  Halstenson, C E ^a   Shamp, T ^a,c   Gargano, M A ^b   Walsh, R M ^b   Patchen, M L ^b  

^a Prism Research   (United States)

^b Biothera   (United States)

^c Respiratory Consultants   (United States)

Author keywords

Beta glucan; BTH1677; Imprime PGG; Pathogen associated molecular pattern; Pharmacokinetics; Safety

Indexed keywords

BETA(1,6)[POLY(1,3) DEXTRO GLUCOPYRANOSYL]POLY BETA(1,3) DEXTRO GLUCOPYRANOSE; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PLACEBO; UNCLASSIFIED DRUG; BETA GLUCAN; BETA-1,6-GLUCAN; BTH1677; GLUCAN;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLURRED VISION; CHILL; CONJUNCTIVITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; ELIMINATION HALF-LIFE; FATIGUE; FEMALE; FLATULENCE; FLUSHING; GINGIVA PAIN; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; HYPESTHESIA; INJECTION SITE PAIN; INJURY; LACERATION; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MUSCULOSKELETAL STIFFNESS; MYALGIA; NAUSEA; NORMAL HUMAN; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; THORAX PAIN; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VOLUME OF DISTRIBUTION; ADOLESCENT; CLINICAL TRIAL; DEMOGRAPHY; DOSE RESPONSE; YOUNG ADULT;

ADOLESCENT; ADULT; BETA-GLUCANS; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLUCANS; HEALTHY VOLUNTEERS; HUMANS; MALE; PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES; PLACEBOS; YOUNG ADULT;

EID: 84961062810     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-016-0325-z     Document Type: Article

References (26)

1. Bacic A, Fincher G, Stone B (2009) Chemistry, biochemistry, and biology of (1- > 3)-ß-glucans and related polysaccharides. Academic Press-Elsevier Inc, New York
2. Luigina R (2011) Immunity to fungal infections. Nat Rev Immunol 11:275-288
3. Sorrell T, Chen S (2009) Fungal-derived immune modulating molecules. Adv Exp Med Biol 666:108-120
4. Bose N, Chan A, Guerrero F, Maristany C, Qui X, Walsh R, Ertelt K, Jonas A, Gorden K, Dudney C, Wurst L, Danielson M, Elmasry N, Magee A, Patchen M, Vasilakos J (2013) Binding of soluble yeast beta-glucan to human neutrophils and monocytes is complement-dependent. Front Immunol 4:230
5. Jonas A, Qiu X, Chan A, McMurray D, Bose N (2015) Imprime PGG, a yeast beta-glucan immunomodulator, can engage Fc gamma receptor (FcgR) in addition to complement receptor 3 (CR3) on human neutrophils and monocytes (abstract). Keystone Symposium on Tumor Immunology, Multidisciplinary Science Driving Combination Therapy, Banff, Alberta
6. Bose N, Antonysamy M, Patchen M, Lowe J, Mattson P, Gargano M, Gordon K, Leonardo S, Walsh R, Qui X, McMurry D, Chan A, Jonas A, Huhn R, Thomas M, Sadjadian P, Schneller F (2014) Endogenous anti-beta-glucan antibodies as a potential predictive biomarker for clinical resposne to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients (abstract). J Clin Oncol 13(15S):3045
7. Bose N, Jonas A, Qiu X, Chan A, Ottoson N, Graff J (2015c) Imprime PGG treatment enhances antibody-dependent cellular phagocytosis (ADCP) of tumor cells by monocyte-derived macrophages (abstract). AACR the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY
8. Leonardo S, Fulton R, Wurst L, Gorden K, Jonas A, Qui X, Chan A, Graff J (2015a) Imprime PGG binds to neutrophils through complement, Fc, and dectin-1 receptors, priming these cells for enhanced ROS production and tumor cell cytotoxicity (abstract). AACR the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY
9. Chan A, Qiu X, Bykowski Jonas A, Patchen M, Bose N (2014) Imprime PGG, a yeast beta glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype (abstract). J Immunother Cancer 2(Suppl 3):P191
10. Chan A, Qiu X, Bykowski Jonas A, Kangas T, Ottoson N, Bose N (2015) Imprime PGG modulates the function of monocyte-derived M2 macrophages and dendritic cells to drive T cell expansion (abstract). Cancer Res 75(Suppl 15):LB225
11. Fraser K, Ottoson N, Qiu X, Chan A, Bykowski Jonas A, Kangas T, Graff J, Bose N (2015) Imprime PGG modulates the myeloid component of the tumor microenvironment to coordinate an anti-tumor immune response (abstract). AACR international conference on frontiers in basic cancer research. PA, Philadelphia
12. Leonardo S, Fulton R, Wurst L, Gorden K (2015b) Imprime PGG decreases regulatory T cell suppression and enhances T cell proliferation and differentiation revealing additional mechanisms for its anti-tumor activity (abstract). Cancer Res 75(Suppl 15):5034
13. Bose N, Fulton R, Chan A, Leonardo S, Fraser K, Jonas A, Ottoson N, Qiu X, Gorden K, Graff J (2015a) Imprime PGG, a yeast-derived Pathogen-Associated Molecular Pattern (PAMP), drives a coordinated anti-cancer immune attack (abstract). Symposia on Cancer Research: Emerging Concepts in Host Response to Cancer, Houston, TX
14. Bose N, Chan A, Jonas A, Qiu X, Ottoson N, Kangas T, Graff J (2015b) Imprime PGG treatment elicits a coordinated antitumor immune response that triggers enhanced expression of PD-L1 on tumor cells as well as monocyte-derived macrophages and dendritic cells. Cancer Res 75 (Suppl 15):LB-228
15. Fulton R, Leonardo S, Michel K, Danielson M, Gorden K, Graff J (2015) Imprime PGG, a soluble beta-glucan, binds to and activate dendritic cells resulting in enhanced T cell priming, expansion, and cytokine production (abstract). AACR the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, Philadelphia, PA
16. Li B, Allendorf DJ, Hansen R, Marroquin J, Ding C, Cramer DE, Yan J (2006) Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol 177:1661-1669
17. Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR, Yan J (2011) Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. Blood 117:6825-6836
18. Li B, Allendorf DJ, Hansen R, Marroquin J, Cramer DE, Harris CL, Yan J (2007) Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res 67:7421-7430
19. Salvador C, Li B, Hansen R, Cramer DE, Kong M, Yan J (2008) Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res 14:1239-1247
20. Zhong W, Hansen R, Li B, Cai Y, Salvador C, Moore G, Yan J (2009) Effect of yeast-derived beta glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models. J Immunother 32:703-712
21. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2005) Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Rockville, MD USA
22. Tamayo M, Cornelio G, Bautista J (2010) Safety, pharmacokinetics (PK), and efficacy of imprime PGG plus cetuximab (cetux) with and without irinotecan (irino) in advanced metastatic colorectal cancer (mCRC) patients (abstract). Ann Oncol 21(Suppl 8):4584
23. Segal N, Senzer N, Gada P (2011) Imprime PGG plus cetuximab therapy for advanced KRAS mutant colorectal cancer (abstract). Ann Oncol 22(Suppl 5):PD0013
24. Schneller F, Thomas M, Sadjadian P, Kollmeier J, Bose N, Antonysamy M, Patchen M, Lowe J, Mattson P, Huhn R (2014) PGG beta glucan with carboplatin, paclitaxel and cetuximab for chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC) (abstract). J Thorac Oncol 9(Suppl 14):S40
25. Engel-Reidel W, Schneller F, Wolf M, Schuette W, Lowe J, Mattson P, Gargano M, Patchen M, Huhn R, Ma B, Braun A (2015) Imprime PGG, a novel immune modulator, combined with carboplatin, paclitaxel and bevacizumab for 1st line advanced nonsquamous NSCLC (abstract). J Thorac Oncol 10(Suppl 2):S642
26. Zent CS, Call TG, Bowen DA, Conte MJ, LaPlant BR, Witzig TE, Ansell SM, Weiner GJ (2015) Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. Leuk Lymphoma 56:2373-2378